Cargando…
The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma
Although the mortality rate of osteosarcoma (OS) patients has improved, there are still many unsolved problems concerning how to reduce recurrence and metastasis. In the tumor microenvironment, immune escape plays a more important role in tumor progression and development. Many costimulatory molecul...
Autores principales: | Fan, Meng-ke, Qi, Li-li, Zhang, Qi, Wang, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850464/ https://www.ncbi.nlm.nih.gov/pubmed/33536783 http://dx.doi.org/10.2147/CMAR.S285560 |
Ejemplares similares
-
An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021) -
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
por: Mao, Lili, et al.
Publicado: (2021) -
Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy
por: Flies, Dallas B., et al.
Publicado: (2011) -
Exceptional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma with tumor site infection
por: Li, Meng, et al.
Publicado: (2022) -
H(1 )Antihistamines: Current Status and Future Directions
por: Simon, F Estelle R, et al.
Publicado: (2008)